Stem-cell-based Therapies for Improving Islet Transplantation Outcomes in Type 1 Diabetes
Cunha, Joao P M C M LU
; Gysemans, Conny
; Gillard, Pieter
and Mathieu, Chantal
(2018)
In Current Diabetes Reviews
14(1).
p.3-13
- Abstract
INTRODUCTION: Beta-cell replacement by human islets or whole pancreas offers a life-saving therapeutic remedy for patients suffering from type 1 diabetes, providing considerable advantages with respect to diminishing total daily insulin dose and lowering frequencies of debilitating hypoglycemic reactions as well as preventing chronic micro- and macrovascular complications. Although remarkable progress has been made in this area, several hurdles remain, hampering its wide-spread applicability. Such hurdles include a limiting supply of islets, the necessity of several donors to achieve enough islet mass for insulin independence, and graft failure because of metabolic pressure, continued autoimmunity, alloimmunity, high concentrations of... (More)
INTRODUCTION: Beta-cell replacement by human islets or whole pancreas offers a life-saving therapeutic remedy for patients suffering from type 1 diabetes, providing considerable advantages with respect to diminishing total daily insulin dose and lowering frequencies of debilitating hypoglycemic reactions as well as preventing chronic micro- and macrovascular complications. Although remarkable progress has been made in this area, several hurdles remain, hampering its wide-spread applicability. Such hurdles include a limiting supply of islets, the necessity of several donors to achieve enough islet mass for insulin independence, and graft failure because of metabolic pressure, continued autoimmunity, alloimmunity, high concentrations of immunosuppressive drugs as well as oxidative stress caused by hypoxia or inflammation. On the other hand, the islet transplant procedure provides the possibility to undertake multiple practical and beneficial manipulations of the beta cells before engraftment with the intention to reach improved graft survival results.
CONCLUSION: We have focused on the current status of various obstacles in islet transplantation and on the potential of (stem)cell-based treatments able to stimulate islet graft outcome in pre-clinical and clinical transplantation settings in which specific attention is given to the engraftment-enhancing and immunomodulatory potential of various types of stem cells..
(Less)
- author
- Cunha, Joao P M C M
LU
; Gysemans, Conny
; Gillard, Pieter
and Mathieu, Chantal
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Animals, Diabetes Mellitus, Type 1/immunology, Graft Survival, Humans, Islets of Langerhans Transplantation/adverse effects, Stem Cell Transplantation/adverse effects, Transplantation Immunology, Treatment Outcome
- in
- Current Diabetes Reviews
- volume
- 14
- issue
- 1
- pages
- 3 - 13
- publisher
- Bentham Science Publishers
- external identifiers
-
- scopus:85042348350
- pmid:27363412
- ISSN
- 1573-3998
- DOI
- 10.2174/1573399812666160629094031
- language
- English
- LU publication?
- no
- id
- a3ae3dac-0a24-4c50-af18-7e38692172b7
- date added to LUP
- 2019-02-14 09:43:55
- date last changed
- 2024-04-15 23:21:19
@article{a3ae3dac-0a24-4c50-af18-7e38692172b7,
abstract = {{<p>INTRODUCTION: Beta-cell replacement by human islets or whole pancreas offers a life-saving therapeutic remedy for patients suffering from type 1 diabetes, providing considerable advantages with respect to diminishing total daily insulin dose and lowering frequencies of debilitating hypoglycemic reactions as well as preventing chronic micro- and macrovascular complications. Although remarkable progress has been made in this area, several hurdles remain, hampering its wide-spread applicability. Such hurdles include a limiting supply of islets, the necessity of several donors to achieve enough islet mass for insulin independence, and graft failure because of metabolic pressure, continued autoimmunity, alloimmunity, high concentrations of immunosuppressive drugs as well as oxidative stress caused by hypoxia or inflammation. On the other hand, the islet transplant procedure provides the possibility to undertake multiple practical and beneficial manipulations of the beta cells before engraftment with the intention to reach improved graft survival results.</p><p>CONCLUSION: We have focused on the current status of various obstacles in islet transplantation and on the potential of (stem)cell-based treatments able to stimulate islet graft outcome in pre-clinical and clinical transplantation settings in which specific attention is given to the engraftment-enhancing and immunomodulatory potential of various types of stem cells..</p>}},
author = {{Cunha, Joao P M C M and Gysemans, Conny and Gillard, Pieter and Mathieu, Chantal}},
issn = {{1573-3998}},
keywords = {{Animals; Diabetes Mellitus, Type 1/immunology; Graft Survival; Humans; Islets of Langerhans Transplantation/adverse effects; Stem Cell Transplantation/adverse effects; Transplantation Immunology; Treatment Outcome}},
language = {{eng}},
number = {{1}},
pages = {{3--13}},
publisher = {{Bentham Science Publishers}},
series = {{Current Diabetes Reviews}},
title = {{Stem-cell-based Therapies for Improving Islet Transplantation Outcomes in Type 1 Diabetes}},
url = {{http://dx.doi.org/10.2174/1573399812666160629094031}},
doi = {{10.2174/1573399812666160629094031}},
volume = {{14}},
year = {{2018}},
}